Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs (CHANCE Study)

Clinical Trial Details

This observational trial is for men or women who have been diagnosed with a chronic liver disease known as cirrhosis.

Liver cirrhosis is often associated with the failure of other organs or systems, known as acute-on-chronic liver failure (ACLF). Studying the progress of patients with this disease will be of great clinical use and will contribute to improving the design of potential treatments more appropriately. 
The purpose of this study is to see the progress of patients with cirrhosis who receive transplants and who do not receive transplants. This study will compare 1‐year graft and patient survival rates after liver transplantation (LT) in individuals with ACLF at the time of LT to individuals with decompensated cirrhosis (liver deterioration) without ACLF at the time of LT, as well as transplant‐free survival of patients with ACLF not listed for LT.

In addition, individuals will have the opportunity to participate in an optional collection of biological samples. The biological samples will be used to evaluate the impact of the transplant on parameters not usually evaluated in clinical practice.
Participation in this study will last about 3 years (36 months).

Key Eligibility: 
  1. Men and women who are 18 years of age and older.
  2. Individuals with been diagnosed with liver cirrhosis.

Detailed eligibility reviewed when contacting the study team.


Study contact by location

Upper East Side - Manhattan


GI/ Hepatology
(646) 962-4040

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




EF CLIF Protocol 2020/01325


Open to Enrollment

Age Group